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http:WHAT THIS PAPER ADDS
The systematic review (and meta-analysis) of current evidence focuses on clinical outcomes that support an
inverse relationship between diabetes and abdominal aortic aneurysms (AAA), and higher mortality in diabetic
patients with AAA either in the operative period or in the long term. The increased cardiovascular burden and
the decreased risk for AAA development and expansion suggest careful and individualized selection of diabetic
patients for treatment of AAA in the future.Epidemiologic evidence suggests that patients with diabetes may have a lower incidence of abdominal aortic
aneurysm (AAA); however, the link between diabetes and AAA development and expansion is unclear. The aim of
this review is to analyze updated evidence to better understand the impact of diabetes on prevalence, incidence,
clinical outcome, and expansion rate of AAA. A systematic review of literature published in the last 20 years using
the PubMed and Cochrane databases was undertaken. Studies reporting appropriate data were identiﬁed and a
meta-analysis performed using the generic inverse variance method. Sixty-four studies were identiﬁed.
Methodological quality was “fair” in 16 and “good” in 44 studies according to a formal assessment checklist
(NewcastleeOttawa). In 17 large population prevalence studies there was a signiﬁcant inverse association
between diabetes and AAA: pooled odds ratio (OR) 0.80; 95% conﬁdence intervals (CI) 0.70e0.90 (p ¼ .0009). An
inverse association was also conﬁrmed by pooled analysis of data from smaller prevalence studies on selected
populations (OR 0.59; 95% CI 0.35e0.99; p ¼ .05), while no signiﬁcant results were provided by case-control
studies. A signiﬁcant lower pooled incidence of new AAA in diabetics was found over six prospective studies: OR
0.54; 95% CI 0.31e0.91; p ¼ .03. Diabetic patients showed increased operative (30-day/in-hospital) mortality
after AAA repair: pooled OR 1.26; 95% CI 1.10e1.44; p ¼ .0008. The increased operative risk was more evident in
studies with 30-day assessment. In the long-term, diabetics showed lower survival rates at 2e5 years, while there
was general evidence of lower growth rates of small AAA in patients with diabetes compared to non-diabetics.
There is currently evidence to support an inverse relationship between diabetes and AAA development and
enlargement, even though fair methodological quality or unclear risk of bias in many available studies decreases
the strength of the ﬁnding. At the same time, operative and long-term survival is lower in diabetic patients,
suggesting increased cardiovascular burden. The higher mortality in diabetics raises the question as to whether
AAA repair should be individualized in selected diabetic populations at higher AAA rupture risk.
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The epidemiology of abdominal aortic aneurysms (AAA) is
becoming more clearly deﬁned with data emerging from
screening studies and vascular biology research. It has been
suggested that AAAs arise when genetically susceptible in-
dividuals are exposed to additional risk, such as smoking
and increasing age. The pathologic process involved in therresponding author. P. De Rango, Vascular and Endovascular Unit,
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//dx.doi.org/10.1016/j.ejvs.2013.12.007formation of a degenerative AAA is complex, involving up-
regulation of proteolytic pathways, apoptosis, oxidative
stress, inﬂammation, and loss of arterial wall matrix.1e3
Speciﬁcally, matrix loss is seen in the walls of aneurysmal
aorta, while, on the contrary, an excess vascular matrix is a
characteristic of diabetes. For individuals developing dia-
betes, it is possible that increases in matrix due to their
diabetes compensate for any decrease related to suscepti-
bility to AAA. Epidemiologic evidence therefore suggests
that patients with diabetes may have a lower incidence of
AAA. However, the precise mechanisms of this inverse as-
sociation are unknown, and the link between diabetes and
AAA development and expansion is unclear. There is also
limited information on clinical outcome in patients with
244 P. De Rango et al.diabetes and AAA receiving or not receiving treatment. The
aim of this review was to analyze updated evidence to
better understand the impact of diabetes on prevalence,
incidence, and clinical outcome of AAA. The effect of dia-
betes on AAA expansion was also reviewed.METHODS
A literature search of published studies on diabetes and
AAA was performed following quality reporting guidelines
set by the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses.4
MEDLINE, Cochrane Database of Systematic Reviews, and
Cochrane Central Register of Controlled Trials were
searched to identify studies published in the last 20 years
(between 1 January 1993 and 20 July 2013) using the
following key search words: “diabetes” OR “glycemia” AND
“abdominal aortic aneurysms”, “prevalence”, “incidence”,
“growth”, “enlargement”, and “outcomes”. No ﬁlters were
used to restrict study designs. In addition, reference lists
were searched for further studies to be included.
Two researchers (P.D.R., L.F.) independently performed
abstract, title, and full-text screening. Studies were
included if they reported on AAA with a baseline diameter
of at least 3 cm and provided data for diabetic patients
(distribution of disease, and clinical/morphology outcomes
as mortality, morbidity after repair, and aneurysm
enlargement). Studies reporting on aortic aneurysms
involving the thoracoabdominal or thoracic aorta were
excluded unless thoracic aneurysms were used as a control
group for AAA. In addition, the following were excluded:
review articles, studies in which patient data were dupli-
cated (in which case, the most recent or comprehensive
study was used), nonhuman studies, editorials, letters, and
case reports.
Where possible, the following data were extracted from
each report: study period, study design, country of origin,
source of patients (population screening, hospital
screening, case-control), deﬁned diabetic patients, sex,
intervention policy, duration of follow-up (mean, median),
outcomes (e.g., 30-day in hospital mortality, aortic diameter
measurement), analysis (statistical methods used, employ-
ment of univariate or adjusted calculations).
The same two authors independently extracted data from
the potentially eligible primary studies and cross-checked
their results. Any disagreements between the two re-
viewers were settled with discussion and re-analysis of the
paper data, and resolved by mutual consent.
Studies that failed to provide essential variables (e.g.,
diabetic patients or AAA) were rejected.
The effect of diabetes on patients with AAA was inves-
tigated for the following outcome measures:
1. Prevalence and incidence of AAA in patients with
diabetes
2. Mortality in patients with diabetes and AAA
3. Risk of aneurysm enlargement in patients with diabetes
and small AAA.Assessment of methodological quality and risk of bias
All the included studies were non-randomized for the study
populations (diabetics, non-diabetics), with no level 1 evi-
dence. The quality of these observational studies was
evaluated using the “NewcastleeOttawa Scale” (adopted by
Wells et al.5), including assessment of selection, compara-
bility, and outcome/exposure of patients in cohort and case-
control studies. In addition, the US Preventive Services Task
Forces checklist (adopted by Sawaya et al.6), including
assessment of quality in reporting, confounding bias, and
external validity was used to score included studies.
Risk of bias assessment. The main scoring of the included
studies in this systematic review was based on assessment
of “risk of bias” more than generic “methodological quality
“assessment. Bias may be distinguished from quality.7
“Assessment of methodological quality” has been used
extensively to refer to the critical appraisal of included
studies. The term suggests an investigation of the extent to
which study authors conducted their research to the high-
est possible standards. A study may be performed to the
highest possible standards yet still have an important risk of
bias. For example, in randomized trials, it could be that no
random allocation was allowed for the populations of in-
terest in the present review (i.e., diabetic patients). In many
situations, despite the incidence of AAA being tested with
adjustments for several confounders, no blinding in testing
the association with diabetes was clearly used or
mentioned. Risk of bias was rated as “low”, “unclear” (items
not-known or not-reported), or “higher” as in the Cochrane
checklist.7
A summary of the main characteristics of bias and quality
score systems is shown in Supplementary Tables 1A and 1B.Statistical analysis
Studies were separately analyzed according to whether they
reported on prevalence, clinical outcomes, or aneurysm
growth using RevMan v.5.1 (The Cochrane Collaboration,
http://ims.cochrane.org/revman).7
For dichotomous outcomes such as mortality and the
prevalence/incidence of AAA, studies with estimates from
two treatment arms were pooled to obtain an overall study
estimate. The overall estimates (one for each study), such as
risk ratio (RR), hazard ratio (HR), or odds ratio (OR) with
corresponding conﬁdence intervals (CIs), were then com-
bined in a conventional meta-analysis using the generic
inverse variance option in RevMan where the log RRs for
cohort studies or log ORs for case-control studies and cor-
responding standard errors (SE) were weighted to obtain a
pooled estimate.7 As in other meta-analyses, ORs were
considered as approximations of RRs.8 Both random- and
ﬁxed-effect models were used depending on the level of
heterogeneity among studies. Adjusted estimates of risk
were employed when available. If data had been presented
in other forms, we entered total and number of events,
respectively, into RevMan 5.1 and ﬁrst calculated study
estimates (OR with corresponding SE) and then used the
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effects weighting.
Interstudy heterogeneity was assessed by Cochrane’s Q
(chi-square p < .10) and quantiﬁed by I2. The I2 statistic was
used to estimate the percentage of variability between
studies because of between-study heterogeneity.7 An I2
50% indicated “substantial” heterogeneity and 75%
indicated “considerable” heterogeneity.7,8
To assess the association of diabetes and AAA, large ul-
trasound case-cohort studies, case-cohort screening studies
in selected populations, and case-control studies were
assessed separately. Subgroup analyses were performed to
investigate the effect of diabetes in speciﬁc settings with
information available (e.g., women and men, study design).Figure 1. Flow chart ofFor continuous measures, such as aneurysm growth, we
aimed to analyze weighted mean differences using means
and SDs. When these data were not available, we reported
summary data with means and ranges, but did not include
these results in a meta-analysis.
RESULTS
Search results
Fig. 1 shows the ﬂow of the literature selection applying the
systematic search and selection strategies to identify
eligible reports. Three hundred and eighty-nine reports
were identiﬁed. Of these, 228 were found to be irrelevant
on a review of the titles and abstracts.selection of articles.
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reviewed in full, 12 were excluded because they did not
contain original data and 23 because they were separate
publications at different times of the same study/authors
group. Only the most recent or the most comprehensive
publication of the results was included in the analyses as
representing the cumulative experience of the overall
cohort. After full-text evaluation, 64 articles that provided
information on the association between diabetes and AAA
were selected (Tables 1e4).9e72 The RESCAN publication,65
even though it is a review including data from previous
studies, was retained because of relevant information pro-
vided within. The results of this review were not combined
with other data already included.
Of the selected 64 articles, 31 reported on the prevalence
of AAA in diabetic patients9e39 and six were prospective
studies analyzing the incidence of AAA in diabetics.40e45
Nineteen provided information on clinical outcome of dia-
betic patients with AAA undergoing surgery or not or
endovascular repair (EVAR).46e64 Eight additional studies
provided data on the morphology outcome of small AAA
and analyzed the aneurysm growth with diabetic status.65e
72 Cumulative quantitative analyses were possible on 54
studies.Quality and risk of bias score results
Overall score risk of bias for each of the 64 individual
studies was judged to be “unclear” in 23 and “lower” in 38
studies (Supplementary Figs. 1A, B). No studies at higher
bias risk were included in quantitative analysis of data.
The overall methodological quality of most of the
included studies was rated as “fair” (n ¼ 16) or “good”
(n ¼ 44) according to the formal assessment checklist.
Details of bias and quality score assessment of included
studies is shown in Supplementary Tables 1A and 1B.Results on prevalence of AAA and diabetes
Most of the retrieved papers were ultrasound screening
AAA studies that reported on the association between
diabetes and AAA. Table 1 shows the main characteristics of
the 31 selected studies, which included 17 large screening
populations,9e25 ﬁve selected screening populations (e.g.,
AAA screening in patients undergoing cardiac surgery)26e30
and nine case-control studies.31e39
Nine of these studies were rated at “low” risk of bias, and
multivariate assessment of confounders other than diabetes
was available.12,14,20e22,31,32,34,38
Overall, in 10 studies a signiﬁcant inverse association was
recorded between diabetes and AAA. Most of the opposite
relationship supporters were large screening population
studies14,20e22 or case-control studies,31e35 whereas
screening studies with smaller samples were often incon-
clusive,27,29,30 and only one sustained the inverse associa-
tion.26 Three studies provided an opposite positive
association between AAA and diabetes,28,38,39 but only in
one were adjusted data provided.38Depending on the availability of required information,
two studies providing incomplete data could not be
included27,28 in the cumulative analysis of the association
between diabetes and AAA that involved a total 38,900
patients with AAA and 3,296,269 without AAA.
Lederle et al.13,14 performed two cohort studies. Com-
bined data of the two cohorts, provided by the authors in
their most recent article, were used.14 Furthermore, the
studies of Lederle et al.13,14 provided separate information
for AAA with a diameter of 3e3.9 cm and those with a
diameter of >4 cm, and data were analyzed accordingly.
Cumulative analysis of overall prevalence studies sug-
gested lower AAA rates in diabetic patients (pooled OR
0.79; 95% CI 0.70e0.89; p ¼ .0001). Separate data were
provided for large cohort screening, selected populations
screening, and case-control studies.
According to all cohort studies (large screening and
selected population) a signiﬁcantly lower association be-
tween AAA and diabetes was found (OR 0.79; 95% CI 0.69e
0.89; p ¼ .002).
Speciﬁcally, cumulative analysis from the 17 large
screening population studies9e25 showed a signiﬁcant in-
verse association between diabetes and AAA among 33,407
patients with AAA and 3,290,604 without AAA (OR 0.80;
95% CI 0.70e0.90; p ¼ .0009) (Fig. 2). A signiﬁcant inverse
association between diabetes and AAA prevalence was also
conﬁrmed when the pooled analysis was restricted to the
ﬁve screening population studies with lower risk of
bias12,14,20e22 (OR 0.66; 95% CI 0.57e0.75; p < .00001)
(Fig. 2B).
The overall risk of bias of the three26,29,30 studies
analyzing the association between diabetes and AAA in
selected populations (e.g., patients undergoing cardiac
surgery or with acute coronary syndromes) was “unclear”.
Cumulative analysis of the data from the three studies
showed a borderline inverse association between diabetes
and AAA prevalence (OR 0.59; 95% CI 0.35e0.99; p ¼ .05).
Inter-study heterogeneity was <75%, and a ﬁxed-effect
model was used (Fig. 3).
According to cumulative data from case-control studies,
including 5,390 patients with AAA and 4,873 controls with
other diseases or healthy population,31e39 there was no
signiﬁcant association between diabetes and AAA either in
all studies (OR 0.69; 95% CI 0.40e1.18; p ¼ .17) or when
only the four studies at low risk of bias were combined
(Fig. 4A, B).
Large cohort screening studies weighted for most of the
overall effect on prevalence of AAA in diabetics. The dif-
ference among the effects of different study design is
shown in Supplementary Figs. 2A and 2B, where compari-
son between large screening studies versus selected pop-
ulation studies and all cohort prevalence studies versus
case-control studies are displayed.Results on incidence of AAA and diabetes
Six prospective large population studies evaluating the risk
of long-term AAA occurrence in diabetic and non-diabetic
Table 1. Abdominal aortic aneurysms (AAA) and diabetes. Prevalence studies.
Study Diabetes
with AAA
AAA Diabetes
no AAA
Without AAA Total OR 95% CI p Comments
Screening studies: large populations
Smith et al., 19939 11 219 143 2,378 2,597 Population. No signiﬁcant association of
diabetes/AAA
Pleumeekers et al., 199510 8 112 509 5,192 5,304 Rotterdam study.
No signiﬁcant association of diabetes/AAA
Simoni et al., 199611 10 70 212 1,504 1,574 .964 Genoa population. No signiﬁcant association of
diabetes/AAA
Kanagasabay et al., 199612, a 11 218 234 5,122 5,340 Adj.a 0.80a 0.41e1.58a .50 Population No signiﬁcant association of diabetes/
AAA
Lederle et al., 199713, b 73,451 ADAM population early cohort. Signiﬁcant
negative association of diabetes/AAA3.0e3.9 cm 2,217 0.68 0.60e0.77
>4.0 cm 985 0.54 0.44e0.65
Lederle, et al. 200014, a, b 52,745 Adj.a ADAM population new cohort. Signiﬁcant
negative association of diabetes/AAA3.0e3.9 cm 1,237 0.60a 0.50e0.71a
>4.0 cm 583 0.50a 0.39e0.65a
Ishikawa et al., 199915 8 43 173 2,471 2,514 NS Population. No signiﬁcant association of
diabetes/AAA
Lederle et al., combined
199713 þ 200014, a, c
5,023 114,419 119,442 Adj.a ADAM population. Cumulative signiﬁcant
negative association of diabetes/ AAA
3.0e3.9 cm 3,455 0.65a 0.59e0.72a
>4.0 cm 1,568 0.52a 0.45ea0.61
Newman et al., 200116 43 416 505 4,318 4,734 Cardiovascular health study. Medicare. Small
AAA. No signiﬁcant association of diabetes/AAA
Singh 200117 men
(HbA1cþ)
14 263 148 2,699 2,962 .7 Tromso study. Men. No signiﬁcant association of
HbA1c/AAA
Singh et al., 200117
women (HbA1cþ)
4 74 184 3,350 3,424 .4 Tromso study. Women. No signiﬁcant association
of HbA1c/AAA
Waterhouse, et al. 200618 2 30 39 1,202 1,032 Population Men. No signiﬁcant association of
diabetes/ AAA
DeRubertis et al., 200719 10 74 1,312 9,938 10,012 1.20 0.60e2.36 .61 Women. No signiﬁcant association of diabetes/
AAA
Le et al., 200720, a 103 933 1,375 11,270 12,203 Adj. 0.79a 0.63e0.98 Health in men study
Men. Signiﬁcant negative association of diabetes/
AAA
Baumgartner et al., 200821, a 507 1,722 29,539 66,514 68,236 Adj. 0.59a 0.53e0.66 <.0001 REACH Registry Population with thrombotic risks
Signiﬁcant negative association of diabetes/AAA
Kent et al., 201022, a 3,236 2,3446 324,532 3,033,009 3,056,455 Adj. 0.75a 0.73e0.77 <.0001a Lifeline screening. Signiﬁcant negative association
of diabetes/AAA
Palombo et al., 201023 66 512 809 7,722 8,234 .15 No signiﬁcant association of diabetes/AAA
Svensjö et al., 201124 25 233 1,754 14,378 14,611 .51 National population registry Sweden. No
signiﬁcant association of diabetes/AAA
Svensjö et al., 201225
(women)
2 19 498 5,120 5,139 1.09 0.25e4.74 .907 Women. National population registry Sweden. No
signiﬁcant association of diabetes/ AAA
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Table 1-continued
Study Diabetes
with AAA
AAA Diabetes
no AAA
Without AAA Total OR 95% CI p Comments
Screening studies: selected populations
Kang et al., 199926 10 68 98 306 374
2,990a
Adj.a Screening in carotid stenosis. Signiﬁcant negative
association of diabetes/AAA>3 cma 0.58a .002a
>4 cma 0.32a .002a
Hanly et al., 200627, b 41 374 415 1.22 .65 Screening in CAD population. No signiﬁcant
association of diabetes/AAA
Shirani et al., 200928, b 53 1,907 1,960 2.32 .033 Screening in CABG population. Positive
association of diabetes/AAA
Dupont et al., 201029 6 15 57 202 217 .38 Screening in CABG. No signiﬁcant association of
diabetes/AAA
Long et al., 201030 4 20 87 284 304 .31 Screening in ACS. No signiﬁcant association of
diabetes AAA
Case-control studies
LaMorte et al., 199531, a 4,682 3,188
appendectomy
Adj. 0.78a Adj. 0.62e0.98a .03 AAA vs. appendectomy. Signiﬁcant negative
association of diabetes in AAA vs. appendectomy
Blanchard et al., 200032, a 12 98 17 102 200 0.70 0.31e1.55 Case-control study. Signiﬁcant negative
association of diabetes in AAA vs. controlAdj. 0.32a 0.12e0.88a
Shteinberg et al., 200033 5 82 26 PAOD 73 PAOD 155 <.001 AAA vs. PAOD. Signiﬁcant negative assessment.
Diabetes in AAA vs PAOD
Barba et al., 200534 29 151 279 PAOD 1,015 PAOD 1,166 RR 0.63 0.41e0.96 .0031 AAA vs. PAOD. Signiﬁcant negative association of
diabetes in AAA vs. PAOD
Madaric et al., 200535, a 1 16 36 no CAD 93 no CAD 109 0.11 0.01e0.83 AAA þ CAD vs. no CAD. Signiﬁcant negative
association of diabetes in AAA vs. control
univariate. Trend multivariate
Adj. 0.12a 0.01e1.03a
Wanhainen et al., 200536 3 35 17 140 175 .77 Cross-sectional AAA vs. age- and sex-matched
control.
No signiﬁcant association of diabetes in AAA vs.
control
Koksal et al., 200737 5 40 7 PAOD 40 PAOD 80 AAA vs. PAOD.
No signiﬁcant association of diabetes in AAA vs.
PAOD
Ito et al., 200838, a 83 211 30 TAA 132 TAA 343 2.20 1.36e3.64 .002 AAA vs. TAA. Positive association of diabetes in
AAA vs. TAAAdj. 1.85a 1.06e3.30a .033a
Parry et al., 201039 13 75 2 90 165 .002 Small AAA men vs. age- and sex-matched control.
Positive association of diabetes in AAA vs.
controls
Note. OR ¼ odds ratio; CI ¼ conﬁdence intervals; HbA1c ¼ glycosylated hemoglobin; PAOD ¼ peripheral artery obstructive disease; CAD ¼ coronary artery disease; TAA ¼ thoracic aortic
aneurysm; Adj. ¼ adjusted; RR ¼ relative risk; NS ¼ not signiﬁcant; ADAM ¼ Aneurysm Detection and Management; CABG ¼ coronary artery bypass surgery; ACS ¼ acute coronary
syndrome.
a Adjusted data available.
b Data not used for meta-analysis (cumulative analysis).
c Data used for meta-analysis.
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Table 2. Abdominal aortic aneurysms (AAA) and diabetes mellitus (DM). Incidence studies.
Study DM with
AAA
New AAA No DM with
AAA
Without
AAA
Total OR 95% CI p Follow-up Comments
Prospective studies: incidence of AAA
Törnwall et al.,
200140, a
4 181 NA 28,952 29,133 RR 0.43a 0.16e1.15a 5.8 y mean Men. Alpha-tocopherol, beta-carotene cancer
prevalence study. No signiﬁcant association of
diabetes/AAA
Rodin et al.,
200341
72 418 2,515 18,856 19,274 30 y mean Chicago Heart Association Detection Project
Industry.
No signiﬁcant assessment of diabetes/AAA
Wong et al.,
200742, a
7 376 NA 38,976 39,352 0.58 0.27e1.22 0.15 16 y over Men. Health professional follow-up study. No
signiﬁcant association of diabetes/AAA0.55a 0.26e1.17a 0.12a
Iribarren et al.,
200743, a
NA 605 NA 104,208 104,813 0.64 0.38e1.09 13 y median Multiphasic health checkups. No sign ass.
diabetes/ AAATotal
diabetes
3,321
0.62a 0.36e1.05a
Lederle et al.,
200844, a
8 184 9,536 161,624 161,808 0.29a 0.13e0.68a 7.8 y mean Women’s health initiative.
Postmenopausal women. Signiﬁcant negative
association of diabetes/AAA
Ohrlander
et al., 201245, a
NA 3,335; NA 243,223; 246,558; Adj.a Adj.a 13 y over Longitudinal Multilevel Analysis Scania (LOMAS)
cohort Signiﬁcant negative association of
diabetes/AAA in women and men
2,351
men,
104,425
men,
106,776
men,
0.38a 0.24e0.61a
984
women
138,798
women
139,782
women
0.41a 0.19e1.88a
Note. OR ¼ Odds ratio; CI ¼ conﬁdence intervals; RR ¼ relative risk; Adj. ¼ adjusted; NA ¼ not available.
a Adjusted data available.
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Table 3. Outcomes in diabetic and non-diabetic patients with abdominal aortic aneurysms (AAA).
Study AAA 30-d mortality Comment 1-year survival 3-year survival Other outcomes
Katz et al., 199446, a 8,185 elective open
Diabetes: 507
No diabetes: 7678
In-hospital
34 (6.7%)
584 (7.6%)
p ¼ .6
No sign in-hospital mortality in diabetics. conﬁrmed in adjusted data
(data not shown).a
No long-term data.
Treiman et al., 199447 568 AAA elective open
Diabetes: 38
No diabetes: 530
30-d
2 (5.3%)
17 (3.2%)
p ¼ NS
No sign of 30-d mortality in diabetics.
No long-term data.
Higher MI and wound
infection 30-day in
diabetics with AAA
and PAOD
Dardik et al., 199948, a 2,335 elective open
Diabetes: 168
No diabetes: 2,167
In-hospital
5 (3.0%)
76 (3.5%)
p ¼ .99a
No sign of in-hospital mortality in diabetics.
No long-term data.
Sasaki et al., 199949, a 79 elective open repairs
in >75-y-olds
Diabetes: 12
No diabetes: 67
In-hospital
2 (16.7%)
6 (9.0%)
p ¼ .268
p ¼ .082a
No sign of in-hospital mortality in >75-y-old diabetics. No
long-term data.
Finlayson et al., 200250
(Medicare)
Elective open AAA 140,577
Diabetes: 11,246 (8%)
No diabetes: 129,331
In-hospital
RR prior
admission:
1.41 95% CI
1.25e1.59a
RR index
admission:
0.76; 95% CI
0.64e0.84a
Higher RR in diabetics based on prior admission; lower
RR in diabetics based on index admission.
No long-term data.
Rayan et al., 200251
(Vascular Surgery Registry)
422 elective open
Diabetes: 52
No diabetes: 370
30-d
2 (3.8%)
5 (1.4%)
p ¼ .19
No sign of 30-d mortality
in diabetics.
No sign of long-term
survival 1e5 year
(p ¼ .21).
1-y:
91.0%
92.6%
3-y:
70.0%
73.5%
5-y:
25.0%
50.9%;
p ¼ .21
Complications higher
in diabetics.
Gioia et al., 200552, a 183 open repair surviving
after discharge
Diabetes: 5
No diabetes: 178
No data Only data on readmission
at 6-months.
6-mo readmission
rates higher in
diabetics
OR 6.6; 95%
CI 1.02e42.4;
p ¼ 0.047a
Diehm et al., 200754, a
(EUROSTAR)
6383 EVAR
Diabetes: 810
No diabetes: 5,573
30-d
31 (3.8%)a
212 (2.7%);
p ¼ .270a
No sign of mortality at
30 d and 4 y in diabetics.
4-ya:
diabetes 27.7%
vs. no diabetes
23.4%; p ¼ NS
Rupture
conversion;
p ¼ NS
30-d and 4-y
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McFalls et al., 200755, a
(CARP)
1,598 AAA surgery
Diabetes: 226
No diabetes: 1372
No data No 30-d mortality data.
Higher 2e5 y mortality
in diabetics in univariate.
Not conﬁrmed in Cox
(data not shown)a
2e5-y:
77%
HR: 1.38; 95%
CI: 1.03e1.85;
p ¼ .0
Berge et al., 200856, a 1,041 open or EVAR
EVAR: 136
Open: 905
Diabetes: 67 (12 EVAR)
No diabetes: 974 (124EVAR)
30-d
HR 1.3; 95%
CI 0.6e2.8);
p ¼ .45a
No sign of 30-d mortality
in diabetics. Higher 5-y
mortality in diabetics.
5-y:
HR: 1.79; 95%
CI: 1.27e2.53
p ¼ .001a
Wanhainen et al., 200857, a
(Swedish Registry)
10,691 AAA repair
elective (7,175) and
ruptured (3,516)
Diabetes: 823 (7.7%)
No diabetes: 9,868
30-d
Elective AAA:
OR 1.4; 95%
CI 0.9e2.2;
p ¼ 0.15a
Ruptured AAA:
OR 1.7; 95%
CI 1.2e2.3;
p ¼ .001a
Higher 30-d mortality in diabetics in ruptured AAA.
No high 30-d mortality in diabetics in elective AAA.
No long-term data.
Wassink et al., 200853, a
(SMART)
373 AAA screening study
Diabetes (NCEP MetS): 198
No diabetes: 175
(diabetes deﬁned as NCEP
revised MetS)
No 30-d data
Screening study
No sign of 3-year mortality in MetS
HR at 3.2 y: 1.32; 95% CI: 0.88e1.97)a
Giles et al., 200958, a
(Medicare Propensity
match)
22,830 elective AAA
11,415 EVAR
11,415 open
Diabetes: 3,538 (1,746
EVAR þ 1,792 open)
No diabetes: 19,292
(9,669 EVAR þ 9,623
open)
30-d
EVAR: OR 1;
95% CI 0.7e1.5;
p ¼ .91
Open; OR 1.3;
95% CI 1.1e1.6;
p < .01
No increased risk
in adjusteda
Higher 30-d mortality in diabetics for open AAA and univariate.
No sign of 30-d mortality in diabetics for EVAR and adjusted
data (data not shown).a
No long- term data.
Grant et al., 201159, a 1,936 elective open or
EVAR
Diabetes: 172
No diabetes: 1,764
30-d
15 (8.7%)
83 (4.7%)
OR 1.92; 95%
CI 1.08e3.41;
p ¼ .023
OR 1.94; 95%
CI 1.07e3.51);
p ¼ 0.029a
Higher 30-d mortality in diabetics.
No long-term data.
Continued on next page
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Table 3-continued
Study AAA 30-d mortality Comment 1-year survival 3-year survival Other outcomes
Markovic et al., 201060 12,451 elective EVAR
Diabetes: 1,506
No diabetes: 10,945
In-hospital
OR 0.43; 95%
CI 0.58e3.32;
p ¼ 0.42a
No sign of in-hospital mortality in diabetics.
No long-term data.
Schlösser, et al. 201061, a 3,457 elective AAA repair
Diabetes: 104
No diabetes: 3,353
28 d
HR 1.22 95%
CI 0.68e2.17a
No sign of mortality at
28 d or 1 y. Higher 5-y
mortality in
diabetics.
1-y:
HR: 1.40; 95% CI:
0.94e2.09a
5-y:
HR: 1.35; 95%
CI: 1.01e1.80a
De Rango et al., 201262, a
(CAESAR)
360 small AAA surveillance
Diabetes: 49
No diabetes: 311
No data No 30-d mortality.
Higher 3-y mortality in
diabetic; lower growth.
3-y:
88.0%
96.1%
HR: 7.39; 95%
CI 1.55e35.13;
p ¼ .012a
Lower AAA
growth in
diabetics
Mell et al., 201263, a
(SCCOR)
634 AAA small
Diabetes: 162
No diabetes: 472
No surgery natural
history
No 30-day data. Higher
1e3 y mortality in
diabetics.
1-y:
96.8%
3-y: 83.0%
HR: 2.34; 95%
CI: 1.19e4.60
HR: 2.24; 95%
CI: 1.12e4.47a
Hughes et al., 201364, a 2,110 elective open
Diabetes: 245
No diabetes: 1,865
30-d
13 (5.3%)
66 (3.5%); p ¼ .171
OR 1.4; 95% CI
0.68e2.71a
No sign of 30-d mortality in diabetics.
SSI higher in diabetics.
No long-term data.
SSI higher in
diabetics.
Note. EUROSTAR ¼ European Collaborators On Stent-graft Techniques for Abdominal Aortic Aneurysm Repair; SCCOR: Stanford Abdominal Aortic Aneurysm Specialized Center of Clinically
Oriented Research; CARP ¼ Coronary Artery Revascularization Prophylaxis; SMART ¼ Secondary Manifestations of ARTerial disease; CAESAR: Comparison of surveillance vs. Aortic
Endografting for Small Aneurysm Repair; EVAR ¼ endovascular repair; NCEP ¼ National Cholesterol Education Program; NCEP-R ¼ National Cholesterol Education Program revised;
MetS ¼ metabolic syndrome status; NS ¼ not signiﬁcant; RR ¼ relative risk; CI ¼ conﬁdence interval; HR ¼ hazard ratio; SSI ¼ superﬁcial surgical site infections; MI ¼ myocardial
infarction; PAOD ¼ peripheral obstructive arterial disease.
a Adjusted data available.
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Table 4. Diabetes mellitus (DM) and growth in small abdominal aortic aneurysms (AAA).
Study Small
AAA
Aneurysm growth p Comments
Aneurysm growth in diabetics vs. non-diabetics (mm/y mean difference)
Sweeting et al. 201265, a
(RESCAN)b
5,697
623 DM
0.51 mm/y (95% CI 0.70 to 032)
in diabeticsa
<.001a Adjusted meta-analysis combining 10 studies
on small AAA. Signiﬁcant negative mean
aneurysm growth in diabetics with small AAA
De Rango et al., 201262
(CAESAR)
178
20 DM
0.01 mm/y (IQR 0.12 to 0.1)
in diabetics
Negative growth in diabetics with small AAA
at 3 years
Schlösser et al., 200866, a
(SMART)
147
35 DM
0.91 mm/y (95% CI: 2.2 to 0.36)
in diabeticsa
(e1.2 mm/y (95% CI: e2.4 to 0.04)
in diabetics
.158a
.057
No signiﬁcant negative growth in diabetics
with small AAA. Adjusted (*)analyses
Golledge et al., 200869, a 198
20 DM
0.17 mm/ya .01a Signiﬁcant negative growth in diabetics with
small AAA
Thompson et al., 201067, a 1,232
69 DM
0.95 mm/y (95% CI: e1.66 to e0.25)
in diabeticsa
.01a Signiﬁcant negative growth in diabetics with
small AAA based on diabetic medications
Vega de Céniga et al., 200672 106
15 DM
1.69  5.5 mm/y in diabetics
5.22  6.11 mm/y in non-diabetics
.032 Signiﬁcant lower mean aneurysm growth in
diabetics with small AAA
Brady et al., 200471, a 1,743
75 DM
0.79 mm/y (95% CI: 0.27e1.33)
in diabeticsa
Signiﬁcant negative growth in diabetics with
small AAA
Aneurysm growth rates in diabetic vs. non-diabetics (percentages)
Thompson et al., 201067, a 1,232
69 DM
56% slower growth rates in diabeticsa .01a Signiﬁcant decreased growth rate in diabetics
with small AAA based on diabetic medications
Chang et al., 199768, a 514
88 DM
Expansion rate >1 cm/y: 14.3%
diabeticsa
Expansion rate <1 cm/y: 17.5%
diabeticsa
.1a No signiﬁcant decreased growth in diabetics with
small AAA
Golledge et al., 200869, a 198
20 DM
OR 0.18; 95% CI: 0.06e0.57a Signiﬁcant decreased growth rate in diabetics
with small AAA
Ferguson et al., 201070 652
86 DM
OR 0.37; 95% CI 0.22e0.62a <.0001a Signiﬁcant decreased growth rate in diabetics
with small AAA
De Rango et al., 201262, a
(CAESAR)
178
20 DM
HR: 0.37; 95% CI: 0.15e0.91a
KaplaneMeier: 40.8% in diabetics
85.1% in non-diabetics
.003a Signiﬁcant decreased growth rate in diabetics
with small AAA
Note. CAESAR ¼ Comparison of surveillance vs. Aortic Endografting for Small Aneurysm Repair; SMART ¼ Secondary Manifestations of ARTerial disease; IQR ¼ interquartile range; CI:
conﬁdence interval; OR ¼ odds ratio; HR: hazard ratio.
a Data from adjusted analyses.
b RESCAN study included data from studies of Brady et al.,71 Golledge et al.,69 Thompson et al.,67 Vega de Céniga et al.,72 and Ferguson et al.70
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Figure 2. Cumulative prevalence of abdominal aortic aneurysms in large cohort (population screening) studies. (A) All data. (B) Large cohort
studies at low risk of bias.
254 P. De Rango et al.patients were found (Table 2).40e44 Mean follow-up of
assessment ranged from 5.8 years40 to 30.0 years.41 With
the exception of the study by Rodin et al.,41 adjusted data
on the risk of AAA development were provided. A signiﬁ-
cantly lower probability of AAA development in diabetic
patients was found in the two largest and most recentFigure 3. Cumulative prevalence of abdominal aortic anstudies.44,45 One was the study by Lederle et al.,44 which
focused only on women (161,808 postmenopausal women
included in a women’s health initiative), and the other was
a large Swedish cohort of 246,558 people from the Longi-
tudinal Multilevel Analysis Scania (LOMAS) Study, which
included both women and men.45eurysms in cohort studies in selected populations.
Figure 4. Cumulative prevalence of abdominal aortic aneurysms in case-control studies. (A) All case-control data. (B) Case-control studies
at low risk of bias.
European Journal of Vascular and Endovascular Surgery Volume 47 Issue 3 p. 243e261 March/2014 255Cumulative analysis of 600,938 patients developing 5,099
new AAA showed a signiﬁcant inverse association between
the presence of diabetes and incidence of AAA: OR 0.54;
95% CI 0.31e0.91; p ¼ .03 (Fig. 5).Results on clinical outcomes in diabetic patients with AAA
Quantitative analysis was limited to early outcome data
in diabetic patients with AAA after open or EVAR
repair, as provided by 14 studies (11 at “low” risk ofFigure 5. Cumulative Incidence of new abdominabias).46e51,54,56e61,64 In addition, there was one random-
ized controlled trial comparing EVAR versus surveillance
for small AAA,62 and three surveillance studies on small
AAA.53,55,63 In one of these studies (the SMART cohort
study by Wassink et al.53), the 4-year mortality risk was
stratiﬁed according to the presence of metabolic syndrome
status (MetS) deﬁned as the National Cholesterol Educa-
tion Program revised MetS and not on classical diabetes
status. Details of studies are shown in Table 3 and
Supplementary Tables 1A and 1B.l aortic aneurysm in patients with diabetes.
256 P. De Rango et al.Only one study59 reported clear evidence of increased
operative mortality in diabetics in adjusted and unadjusted
analyses; most of the others showed inconclusive periop-
erative data or increased risk in selected diabetic
groups.50,57,58 Five national US population studies providing
only in-hospital information46,48e50,60 were also separately
analyzed from those with 30-day data.
Cumulative analysis of all 14 studies, including 19,288
diabetic and 193,777 non-diabetic patients with AAA
receiving repair (different types),46e51,54e61,64 showed a
signiﬁcant increased operative mortality in the diabetic
group (OR 1.26; 95% CI 1.10e1.44; p ¼ .0008) (Fig. 6A).
The increased risk in diabetics was more evident inFigure 6. Cumulative operative mortality in patients with abdominal ao
operative mortality data. (C) Studies with in-hospital operative mortalanalysis of perioperative mortality limited to the nine
studies with 30-day assessment (OR 1.32; 95% CI 1.17e
1.49; p < .00001) (Fig. 6B).47,51,54,56e59,61,64 On the
contrary, no signiﬁcant higher risk in diabetics was
shown in the four studies with only in-hospital
information (OR 0.97; 95% CI 0.63e1.50; p ¼ .89)
(Fig. 6C).46,48e50,60
In the long term, diabetics had signiﬁcantly lower survival
in ﬁve studies,55,56,61e63 as assessed at 2e5 years. A higher
risk of complications in diabetics with AAA was also re-
ported.47,51,52,64 Owing to the variability in timing for
assessment and reporting, long-term outcomes were not
combined in a formal meta-analysis.rtic aneurysm and diabetes. (A) All studies. (B) Studies with 30-day
ity data.
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Secondary meta-analyses were conducted to investigate the
association of diabetes and AAA in overall incidence/prev-
alence studies and in sex subgroups. There were no avail-
able data for separate analyses stratiﬁed by other diabetic
subgroups as type or urgency of repair (e.g., EVAR, AAA
open surgery, elective or ruptured AAA).
As prevalence and incidence do not have the same mean-
ing, cumulative data from these studies was assessed in a
secondary meta-analysis. Combining the 35 studies reporting
on prevalence or incidence of AAA in diabetics and non-
diabetics, a signiﬁcantly inverse association between dia-
betes and AAA was conﬁrmed (OR 0.76; 95% CI 0.68e0.86).
Subgroup analyses for association of diabetes and AAA by
sex were available from nine studies in women and 12
studies in men. The cumulative inverse association was less
evident in the 391,234 women (OR 0.9; 95% CI 0.66e1.22;
p ¼ .48) than in the 214,774 men (OR 0.84; 95% CI 0.73e
0.96; p ¼ .01) (Fig. 7).Aneurysm growth in diabetic patients with small AAA
Quantitative analyses of AAA growth in diabetics and non-
diabetics were, overall, of limited strength because mostFigure 7. Cumulative association between diabetes and abdominal aorti
at study; without brackets, results of subgroup analyses by sex in mixdata were already reported in one recent study65 with
different lengths of follow-up. Qualitative data are shown in
Table 4.
There was general evidence of lower growth rates of
small AAA in patients with diabetes compared with non-
diabetics.65e72 No signiﬁcant results were found in two
studies.66,68
Vega de Ceniga et al.72 found a signiﬁcantly smaller mean
AAA growth rate in non-diabetics: 1.69 versus 5.22 mm/
year (p ¼ .032). Similar ﬁndings were also reported in
studies by Brady et al.,71 Golledge et al.,69 Thompson
et al.,67 and Schlösser et al.,66 which showed that growth
rates decreased by 0.79 mm/year, 0.17 mm/year, 0.95 mm/
year, and 1.2 mm/year, respectively.
Data from these and other studies, speciﬁcally analyzing
aneurysm diameter changes as a continuous variable, have
been recently combined in a meta-analysis from the
RESCAN group based on individual data (published and
unpublished) retrieved from 10 studies.65 Accordingly, AAA
growth rates were signiﬁcantly decreased in patients with
diabetes by a mean of 0.51 mm/year.65
Combining the RESCAN data with non-included studies66
provided a mean of 0.52 mm/year (95% CI 0.71
to 0.33) lower growth for AAA in diabetic patients.c aneurysm in women and men. In brackets the only sex population
ed populations.
258 P. De Rango et al.A signiﬁcantly lower AAA growth rate in diabetic patients
was conﬁrmed by the cumulative analysis of three
studies62,69,70 with available information on 902 AAA as
categorical data (OR 0.34; 95% CI 0.22e0.51; p < .0001).
However, a partial overlapping of data could not be
excluded from two of the Australian studies included.69,70DISCUSSION
The present meta-analysis of the effect of diabetes and AAA
was particularly focused on clinical outcomes more than
morphology and the basic science underlying mechanisms
supporting the relationship between diabetes and aneurysm
development. Quantitative analysis of data provided from
available studies suggested that clinical outcomes are poorer
in patients with diabetes and AAA both in the short and long
term. Operative mortality after AAA treatment is increased
in diabetics (OR 1.26; p ¼ .0008) with data that become
more evident when deaths are assessed at 30 days and not
only in-hospital events are included (OR 1.32; p< .00001). A
number of delayed mortality events, especially after open
surgery in diabetic patients, might have been missed if only
in-hospital data were considered. However, there were
limited data in the included studies for outcome analyses in
subgroups in which it could have helped to have known the
speciﬁc effect of endovascular, open, emergency, or elective
repair in diabetic patients with AAA.
This review also conﬁrmed that patients with diabetes
have a lower prevalence of AAA and, when prospectively
followed, they show decreased risk of developing new AAA
or enlarging their AAA compared with non-diabetics. The
inverse association was less evident in the 391,234 women
(OR 0.9; p ¼ .48) than in the 214,774 men (OR 0.84;
p ¼ .01) included. But differences in overall prevalence of
AAA (2.5% in men vs. 0.4% in women) could probably have
affected the ﬁndings.
The effect of diabetes on morphology AAA outcomes,
shown by previous meta-analyses such as that of the
RESCAN group,65 and conﬁrmed in this review, showing
decreased AAA growth rates in diabetic patients (OR 0.34;
p < .0001) would suggest that the application of an indi-
vidualized best-surveillance approach would be better than
an aggressive treatment strategy in diabetic patients with
small AAA.
An inverse relationship between diabetes and AAA
development was initially stated by Lederle73 in the Aneu-
rysm Detection and Management study, and further sup-
ported by more recent, well conducted systematic reviews
on the topic.65,74 The present study also added quantitative
analysis synthesis and included a larger number of studies
to increase the strength of the results. However, the evi-
dence supporting the ﬁndings of the present review, based
on observational studies, is still limited: despite the large
number of articles, the overall quality was “fair” and risk of
bias “unclear” for most of the included studied. Indeed, a
major limitation of this meta-analysis was that all data
currently available for inclusion come from epidemiologic
studies, and lack of blinding in assessing data was common.There were also inherent limitations in the included
studies based on study design. For example, there was the
possibility of missed information in retrospective studies.
Interpretation of the meta-analysis was complicated by the
evidence of heterogeneity among the studies, which may
have resulted from differences in populations, deﬁnition of
AAA and measurements, adjustment factors, and duration
of follow-up. Because of the extreme variability in number,
type, and deﬁnitions of characteristics and confounders
assessed in each included study, meta-regression analysis
adjusting for confounders was not employed to avoid a
misleading interpretation. Summarizing patient character-
istics at each study level might have run the risk of failing to
detect true relationships between these characteristics and
the size of treatment effect. The risk of obtaining a spurious
explanation for variable treatment effects could have
probably appeared higher because of the many character-
istics that differed among the studies included and the
relatively small number of cases. Therefore, we preferred to
use data adjusted for local confounders at each study level
(when the information was available) and combining the
adjusted data. Otherwise, a meta-analysis based on indi-
vidual patient data would have been more instructive.
Furthermore, there was no detailed information to
investigate the type of diabetes (type I vs. type II) and AAA,
even though given the advanced age of most patients with
AAA, diabetes of type II was more likely in most articles.
Finally, the present review also lacks information
regarding the speciﬁc effects of diabetic medication on AAA,
as the information was limited and not reported as standard
in most studies. Nevertheless, in-depth basic scientiﬁc
analysis of mechanisms of AAA formation and the biologic
processes underlying the opposite relationship between
diabetes and AAA was outside the objective of this review.
Treatment regimens used in diabetes may afford protection
against AAA; therefore, additional explanations of the in-
verse association of AAA growth and prevalence may be
related to the medical treatment of individuals with dia-
betes.75e78 Increased aortic wall stiffness and decreased
aortic wall remodeling have been reported in diabetic pa-
tients: an excess of vascular matrix (decreased extracellular
matrix proteolysis) is a characteristic of diabetes, while
increased matrix loss is seen in the walls of aneurysmal
aortas.1,74 As to whether these may be a consequence of a
hyperglycemic condition or diabetic drugs is subject to
investigation.1,74e78 It has been suggested that the pleio-
tropic drug family, the thiazolidinediones, may have a pro-
tective effect against AAA in animal models.75 Rosiglitazone
and pioglitazone have been suggested to reduce the
development and rupture of aortic aneurysms, and
decrease expression of matrix metalloproteinase (MMP) in
the AAA wall.76,78 Metformin has been shown to improve
aortic wall elasticity, and decrease MMP-2 and smooth
muscle cell proliferation in the aortic wall.74,77 Neverthe-
less, as of today, data supporting the protective effect of
hypoglycemic or other medications against AAA (e.g., sta-
tins, ﬁbrates) are limited and require more in-depth analysis
of their true efﬁcacy.
European Journal of Vascular and Endovascular Surgery Volume 47 Issue 3 p. 243e261 March/2014 259Conclusions
There is currently evidence to support an inverse associa-
tion between diabetes and AAA development, prevalence,
and enlargement. Furthermore, survival (either in the short
or the long term) is poorer in diabetic patients suggesting
an increased cardiovascular burden regardless of the
treatment given for the presence of AAA. The higher 30-day
mortality after operative treatment and the decreased risk
of growing the aneurysm in diabetics raises the question as
to whether AAA repair should be individualized in selected
diabetic populations at higher aneurysm rupture risk.
However, most of the retrieved information on diabetes
and AAA is currently provided by studies with fair meth-
odological quality or unclear risk of bias, and no strong
epidemiologic data can currently support this suggested
inverse association while the precise mechanism remains
yet to be determined. Properly designed studies are needed
before conclusions can be drawn on the best treatment
choice, including the possibility of pharmacologically
attenuating aneurysm expansion and preventing rupture.
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